Drugs / Trastuzmab deruxtecan
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05894824 | Feb 2024 → Dec 2025 overdue | gastric cancer, gastroesophageal junction adenocarcinoma | Yonsei University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trastuzmab deruxtecan | “T-Dxd(Trastuzmab deruxtecan), Ramucirumab” NCT05894824 ↗ |
| Known as | T-Dxd | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05894824 ↗ |
| Route | Intravenous | “Trastruzumab deruxtecan : One IV infusion every 3 weeks on Day 1 of each 21-day cycle” NCT05894824 ↗ |